Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02375113
Other study ID # CRSGP 2012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2012
Est. completion date December 2014

Study information

Verified date May 2022
Source The University of Texas at San Antonio
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study examining the effect of dietary supplements that contain soy products. The purpose of this study to find out if soy supplementation can help to reduce the storage of a certain kind of fat on the body, visceral fat. Visceral fat is fat found deep in the abdomen; it has the potential to increase the risk of certain health problems.


Description:

Obesity is a leading risk factor for many chronic diseases in the USA. Abdominal fat, specifically visceral fat is metabolically active and can be detrimental to health. Abdominal obesity is especially high in postmenopausal women (prevalence rates 50- 70%) in whom estrogen deficiency may lead to accumulation of excess visceral fat. Although estrogen replacement therapy is effective in preventing visceral fat accumulation, its adverse effects warrant a search for a safer phytochemical that exerts estrogenic properties. Soy, containing isoflavones (estrogen-like compounds), is a promising dietary component in reducing abdominal obesity in menopausal women. The favorable effects of isoflavones were already demonstrated in animal studies.The effects of soy compounds as a dietary component in preventing and reducing abdominal obesity and its associated metabolic abnormalities will be examined among menopausal Women. We will use quantitative magnetic resonance spectroscopy/imaging (qMRS/I) to determine dose and effects of soy supplementation for preventing and treating abdominal adiposity. The results from this study will shed light on the application of soy as a novel dietary approach in preventing and managing abdominal obesity among peri- and early menopausal women.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 2014
Est. primary completion date August 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 45 Years to 60 Years
Eligibility Inclusion Criteria: 1. Between the ages of 45 and 60 2. experiencing irregular menses along with one or more other symptoms of menopause including: vaginal dryness, difficulty sleeping, hot flashes, mood changes, increased abdominal/belly fat, or with cessation of menstrual cycle for no more than three years 3. having a BMI greater than 25 4. Waist circumference greater than 88 cm 5. having the ability to understand study procedures and to comply with them for the entire length of the study. Exclusion Criteria: 1. Have ever been diagnosed with cancer 2. Have tumors in the reproductive system 3. Allergies to soy or milk protein 4. Have known metabolic disorders that may affect body weight and body composition (e.g., hypercortisolism and hypothyroidism, non-alcoholic fatty liver disease) 5. Are receiving hormone replacement therapy or estrogen-like remedy 6. Are taking medications (e.g., thyroid, cortisol/cortisone, ephedra, thermogenics, etc) within 30 days prior to the start of the study. 7. Are emotional or uncontrolled eaters as measured by a brief screening tool Three-Factor Eating Questionnaire (TFEQ), i.e., 3 "yes" to the three emotional eating questions or 2 "yes" to the 2 uncontrolled eating questions.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
soy supplementation
Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months. Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone.

Locations

Country Name City State
United States Human Nutrition Lab, UTSA San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas at San Antonio

Country where clinical trial is conducted

United States, 

References & Publications (1)

Umana CK, Wilmoth S, Pan M, Zhang JQ, Fogt DL, He M. Effects of Soy Supplementation on Abdominal Obesity and Metabolic Risks on Post-Menopausal Women: A Pilot Study. Austin Journal of Obesity & Metabolic Syndrome. (1): 1-6, 2017.

Outcome

Type Measure Description Time frame Safety issue
Primary Body Fat (kg) Total body fat and abdominal fat were measured by DEXA (Hologic QDR Discovery A, Bedford, MA) Study endpoint (6 months post intervention)
Secondary BMI (kg/m^2) Body Mass Index (BMI) was calculated using the equation of weight (kg) over height (m) squared (kg/m^2) Study endpoint (6 months post intervention)
Secondary Blood Pressure (mmHg) Subjects' resting systolic and diastolic blood pressure (SBP and DBP, mmHg) was measured with an electronic sphygmomanometer (Omron, USA). Study endpoint (6 months post intervention)
Secondary Lipid Profile and Fasting Glucose High-density lipoprotein (HDL) (mg/L) normal range > 40 mg/dL Low-density lipoprotein (LDL) (mg/L) normal range <100 mg/dL Triglyceride (TG) (mg/L) normal range <150 mg/dl Fasting glucose (mg/dl) normal range: <100 mg/dl C-Reactive Protein (mg/dl): <3 mg/dl in healthy individuals Study endpoint (6 months post intervention)
Secondary Waist Circumference (cm) Waist Circumference was measured midway between the iliac crest and bottom of the rib cage (cm) Study endpoint (6 months post intervention)
Secondary Insulin Resistance Insulin sensitivity index as measured by homeostasis model assessment-insulin resistance (HOMA-IR Index): Normal range 0.5-1.4 Study endpoint (6 months post intervention)
Secondary Inflammatory Cytokines IL-6 (ng/ml) Inflammatory cytokines IL-6 (ng/ml): 75-80 ng/ml in healthy individuals Study endpoint (6 months post intervention)
Secondary C-Reactive Protein (mg/L) C-Reactive Protein (mg/L) <3 mg/L in healthy individuals Study endpoint (6 months post intervention)
See also
  Status Clinical Trial Phase
Withdrawn NCT04545320 - Effectiveness of High-intensity Interval Training (HIIT) Versus Moderate-intensity Continuous Training (MICT) in Reducing Visceral Fat in Adults With Central Obesity N/A
Completed NCT04807959 - Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program
Completed NCT03665961 - The Association Between Microbiota, Endotoxaemia and the Host Obesity/ Insulin Resistance (MiPOOP Study)
Recruiting NCT05833009 - Acupuncture Treatment for Schizophrenia-related Central Obesity N/A
Completed NCT01881373 - Children's Healthy Living Community Randomized Trial N/A
Recruiting NCT05121844 - Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform N/A
Recruiting NCT05874635 - Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022) N/A
Withdrawn NCT03120390 - Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors N/A
Completed NCT04761081 - Is Physical Activity, Obesity, and Ethnicity Associated With the Tethering and Migration of Pro-inflammatory Monocytes?
Completed NCT04152213 - The Effects of Low Glycemic Index (GI) Diet on Cardiometabolic Outcomes Among Obese Chinese Adults N/A
Completed NCT02987595 - Effects of Lignan-rich Diet on Cardiometabolic Risk Factors N/A
Not yet recruiting NCT03552237 - Effect of Dietary Fiber Supplement on the Intestinal Microbiota Among Schizophrenia Patients N/A
Recruiting NCT06024018 - Effect of High Intensity Electromagnetic Body Shaping on Profile of Metabolism in Obese Men N/A
Withdrawn NCT03091842 - Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer N/A
Completed NCT02320760 - Physical Activity on Prescription in Overweight Older Adults N/A
Active, not recruiting NCT03912272 - 12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat N/A
Completed NCT02010060 - Aerobic Training and Non-Exercise Physical Activity N/A
Completed NCT03815253 - Electro-acupuncture for Central Obesity N/A
Completed NCT01445730 - Fructose Consumption and Metabolic Dysregulation N/A
Completed NCT03279432 - Vitamin D-related Genes and Metabolic Disorders N/A

External Links